Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTF0EGX)

• DTT Name: Coagulation factor VII (F7) DTT Info
• Gene Name: F7

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Factor viia	DMZUW6P	Hemophilia	3B10.0	Approved	[1]

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAX-817	DMB147A	Hemophilia	3B10.0	Phase 3	[2]
Vatreptacog alfa (activated)	DMANKTO	Bleeding disorder	GA20-GA21	Phase 3	[3]
Activated recombinant FVII-albumin fusion protein	DMKY9GI	Hemophilia	3B10.0	Phase 2/3	[4]
Recombinant factor VIIa PEGylated liposomal	DMY3TAD	Factor VII deficiency	3B14	Phase 1/2	[1]
CB-813	DMXQGKL	Hemophilia	3B10.0	Phase 1	[5]
Eptacog alfa	DMAQYRL	Hemophilia	3B10.0	Phase 1	[6]
F-7TG	DML4JXZ	Hemophilia	3B10.0	Phase 1	[1]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 86-6150	DM6R3WC	Hemophilia	3B10.0	Discontinued in Phase 2/3	[7]
RNAPc2	DME9V0I	Colorectal cancer	2B91.Z	Discontinued in Phase 2	[8]

7 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
4-(3,4-Diethoxy-benzylamino)-benzamidine	DMIZXYM	Discovery agent	N.A.	Investigative	[9]
4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine	DME3PUT	Discovery agent	N.A.	Investigative	[9]
Factor-VIIa-XTEN	DMDWSH1	Hemophilia	3B10.0	Investigative	[1]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[10]
Human recombinant factor VIIa	DMARY2Z	Factor IX deficiency	3B11	Investigative	[1]
Long-acting Factor VII conjugate	DMAH0RZ	Bleeding disorder	GA20-GA21	Investigative	[1]
MOD-5023	DMKWBNA	Hemophilia	3B10.0	Investigative	[1]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
• [2] Clinical pipeline report, company report or official report of Baxter.
• [3] Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9.
• [4] ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of Catalyst Biosciences.
• [6] Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs. 2008;22(2):121-36.
• [7] Bayer HealthCare and Maxygen Announce Hematology Agreement. U.S. Securities and Exchange Commission. July 2, 2008.
• [8] rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res. 2009 Jan 1;15(1):208-16.
• [9] Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
• [10] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.